Motor Neurone Disease (MND) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Motor Neurone Disease (MND) Market Outlook
Thelansis’s “Motor Neurone Disease
(MND) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast
Report – 2024 To 2034" covers disease overview, epidemiology, drug
utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Motor Neurone Disease (MND)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
Motor
Neurone Disease (MND) Overview
Motor
Neurone Disease (MND) is also known as Amyotrophic lateral sclerosis (ALS). It
is a debilitating, fatal, late-onset degenerative disorder of the nervous
system characterized by motor neuron degeneration, which leads to progressive
muscle wasting and weakness. The disease progresses rapidly; the median
survival is three to five years, and only 20% of patients are alive five to ten
years after symptom onset. Death usually results from respiratory failure.
Despite the poor prognosis, there is considerable variation in the survival
rate, and up to 10% of people with ALS live for more than eight years from the
onset of the first symptoms. The significant breakthroughs in the etiology and
pathophysiology of ALS are the discovery of various genetic risk factors such
as mutations in SOD1, TARDBP, FUS, C9orf72, TBK1, and NEK1. Most of these risk
factors were discovered only within the last ten years, and extensive research
is underway to uncover the common mechanisms affected by these mutations that
may lead to ALS, such as protein misfolding and aggregation.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment